The new patent (US 8,367,586), which the company claims is the first for its antibody platform, covers the composition of MorphoSys’s Ylanthia that comprises more than 100 billion distinct, fully human antibodies.
Ylanthia library, which uses 36 fixed, naturally-occurring heavy and light chain framework combinations, are optimized using MorphoSys’s proprietary Slonomics technology.
Having higher stability and stress tolerance, Ylanthia will increase shelf life and serum stability of resulting antibody products, claims MorphoSys.
In addition, the higher solubility of Ylanthia benefits patients by providing more convenient ways of administration.
MorphoSys chief scientific officer Marlies Sproll said, "A growing patent portfolio on our new antibody platform Ylanthia is an important factor for a successful partnering process in our core licensing markets, which we intend to intensify during the course of 2013."